Correlation between cytidine deaminase genotype and gemcitabine deamination in blood samples

被引：57

作者：

Giovannetti, E. ^{[1
,2
]}

Laan, A. C. ^{[1
]}

Vasile, E. ^{[3
]}

Tibaldi, C. ^{[3
]}

Nannizzi, S. ^{[2
]}

Ricciardi, S. ^{[2
]}

Falcone, A. ^{[3
]}

Danesi, R. ^{[2
]}

Peters, G. J. ^{[1
]}

机构：

[1] Vrije Univ Amsterdam Med Ctr, Dept Med Oncol, Amsterdam, Netherlands

[2] Univ Pisa, Dept Internal Med, Div Pharmacol, Pisa, Italy

[3] Azienda USL Livorno 6, Dept Oncol, Div Oncol, Livorno, Italy

来源：

NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS | 2008年 / 27卷 / 6-7期

关键词：

gemcitabine; cytidine deaminase; CDA polymorphism; CDA activity;

D O I：

10.1080/15257770802145447

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 [生物化学与分子生物学]; 081704 [应用化学];

摘要：

Cytidine deaminase (CDA) is the major enzyme of gemcitabine inactivation. The aim of this study was to determine whether the CDA Lys27Gln polymorphism influenced gemcitabine deamination in blood samples from 90 lung cancer patients. The polymorphism was studied with Taqman probes-based assay; CDA activity was evaluated by HPLC in cytoplasmic extracts from red blood cells. Mean enzymatic activity was significantly lower in patients carrying the CDA Lys27Lys than in patients with the Lys27Gln or Gln27Gln protein (P < 0.05). CDA genotyping may be useful in screening patients before gemcitabine treatment, in order to identify subjects with lower CDA activity and potentially better clinical outcomes after gemcitabine-based chemotherapy.

引用

页码：720 / 725

页数：6

共 16 条

[1]

Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma [J].